You are here

FDA Approves First Oral-Liquid Form of Heart Failure Drug Spironolactone

New formulation eliminates the need for compounding the drug for patients with swallowing difficulties

The FDA has granted final approval of spironolactone oral suspension, 25 mg/5 mL (CaroSpir, CMP Pharma), the first FDA-approved oral liquid dosage form of the potassium-sparing diuretic spironolactone. The company plans to introduce it early in the fourth quarter of 2017.

According to the company, the new formulation provides a stable, ready-to-use, and consistent liquid treatment option for adult patients, especially those who have difficulty swallowing or who are unable to swallow tablets. “Up until now, these patients have been prescribed a pharmacy-compounded liquid form of spironolactone. The dosing inconsistencies of compounded liquids have long been a persistent challenge for physicians,” said Gerald Sakowski, CEO of CMP Pharma.

Spironolactone oral suspension is indicated for the treatment of New York Heart Association Class III–IV heart failure and reduced ejection fraction to increase survival, manage edema, and reduce the need for hospitalization for heart failure, and is usually administered in conjunction with other therapies. Spironolactone oral suspension is also indicated for use as an add-on therapy for the treatment of hypertension, to lower blood pressure in adult patients who are not adequately controlled on other agents, and as part of comprehensive cardiovascular risk management. Lastly, it is indicated for the management of edema in adult cirrhotic patients when edema is not responsive to fluid and sodium restriction.

Spironolactone oral suspension is contraindicated for patients with the following conditions: hyperkalemia, Addison’s disease, and concomitant use of eplerenone. The most common adverse reaction that occurred at an incidence greater than 5% was the increased occurrence of gynecomastia in men.

Source: CMP Pharma; August 7, 2017.

More Headlines

Drug indicated for use prior to surgery to boost platelet counts
Novel drug is a first-in-class treatment that reduces migraine occurrence
Lucemyra indicated for up to 14 days as part of a long-term treatment plan
Agent can also be used perioperatively in some patients to reduce the need for transfusions
Incidence increased 61% over a 14-year period
First drug approved to treat MS in patients as young as 10 years old
Six states will also participate in the litigation
Drug used in combination with bortezomib, melphalan, and prednisone
Scientists find new molecular target for developing safer pain medications